1Weingart S N, Brown E, Bach P B, et al. NCCN Task Force Report: Oral chemotherapy [J]. Journal of the National Comprehensive Cancer Network Jnccn, 2008, 6 Suppl 3 : S1-S14.
2Gerbrecht B, Kangas T. Implications of capecitabine (Xeloda?) for cancer nursing practice [J]. EUR J ONCOL NURS, 2004, 8, Supplement 1 (0) : S63-S71.
3Tadic D, Spasojevic I B, Tomasevic Z I, et al. Oral administration of antineoplastic agents: the challenges for healthcare professionals. [J]. Journal of B. u. on. Official Journal of the Balkan Union of Oncology, 2015, 20(3): 690-698.
4Ruddy K, Mayer E,Partridge A. Patient adherence and persistence with oral anticancer treatment [J]. CA: A Cancer Journal for Clinicians, 2009, 59(1 ): 56-66.
5Alvarez PM, Martinez L D C N, Ucha SM, et al. Medication non- adherence as a cause of hospital admissions [J]. Farm Hosp, 2014, 38(4) : 328-333.
6Kyngas H, Duffy ME, Kroll T. Conceptual analysis of compliance [J]. JClinNurs, 2000, 9(1): 5-12.
7Neuss MN, Polovieh M, Mcniff K, et al. 2013 updated American Society of Clinical Oneology/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy [J]. J Oneol Pract, 2013, 9(2 Suppl) : 5s-13s.
8Zahrina AK, Norsa' dah B, Hassan NB, et al. Adherence to capecitabine treatment and contributing factors among cancer patients in Malaysia [J]. Asian Pae J Cancer Prev, 2014, 15 (21) : 9225-9232.
9Sedjo R, Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer [J]. BREAST CANCER RES TR, 2011, 125(1) : 191-200.
10Larizza MA, Dooley MJ, Stewart K, et al. Factors Influencing Adherence to Molecular Therapies in Haematology-Oncology Outpatients[J]. EUR J HOSP PHARM-S P, 2006, 36 (2) : 115-118.
